Nonalcoholic Fatty Liver Disease and Abdominal Fat Accumulation According to Vitamin D Status in Patients with Type 2 Diabetes

Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim, Sung Koo Kang, Bo-Yeon Kim*
Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea

Background: Vitamin D deficiency is known to increase the incidence of metabolic syndrome. Nonalcoholic fatty liver disease is a common metabolic disease in patients with type 2 diabetes. This study evaluated nonalcoholic fatty liver disease and abdominal fat accumulation according to 25-hydroxyvitamin D status in patients with type 2 diabetes.

Methods: The study comprised 302 patients with type 2 diabetes. Patients were divided into three groups based upon their 25-hydroxyvitamin D status: vitamin D deficient group (<10 ng/mL), vitamin D insufficient group (≥10 to <20 ng/mL) and vitamin D sufficient group (≥20 ng/mL). Patient clinical and laboratory markers were evaluated retrospectively.

Results: Visceral fat thickness was significantly higher in the vitamin D deficient group. There were no differences in glycemic control, body mass index, and subcutaneous fat thickness correlated with 25-hydroxyvitamin D status. The prevalence of nonalcoholic fatty liver disease was significantly higher in the vitamin D deficient group compared to the vitamin D sufficient and vitamin D insufficient groups. In multivariate logistic analysis, after adjustment for age, sex, body mass index, glycated hemoglobin and homeostasis model assessment of insulin resistance, patients with type 2 diabetes in the vitamin D sufficient group showed significantly lower odds ratio for nonalcoholic fatty liver disease than those within the vitamin D deficient group.

Conclusion: In type 2 diabetes, the vitamin D deficient group showed thicker visceral fat thickness and higher nonalcoholic fatty liver disease prevalence.

Key words: Non-alcoholic fatty liver disease, Vitamin D, Type 2 diabetes mellitus

INTRODUCTION

Recently, vitamin D has been studied as an important factor in the development of many diseases, and its importance is not limited to its classic role in bone health. Many previous works have shown an association between vitamin D deficiency or insufficiency and many disease like cardiovascular disease, cancer, and infection. The relationship between vitamin D levels and the development of type 2 diabetes mellitus and metabolic syndrome has also been a recent focus and many studies have reported that low vitamin D levels are associated with insulin resistance and the onset of metabolic syndrome.

Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease of liver associated with insulin resistance. NAFLD is a common condition among patients with type 2 diabetes and according to a meta-analysis reported in 2016, its comorbidity with type 2 diabetes is about 22.51%. The presence of NAFLD in type 2 diabetes can increase the incidence of vascular complications including car-
diovascular disease.\textsuperscript{13,14} Previous studies have shown that lower levels of vitamin D may contribute to NAFLD and abdominal obesity.\textsuperscript{10,15-17} Furthermore, the negative effect of low vitamin D levels on insulin resistance and vascular complications of type 2 diabetes has recently been suggested.\textsuperscript{18-20} Still, the underlying mechanism for the association between vitamin D levels and NAFLD is not entirely known and more human research is needed. In this study, we evaluated NAFLD and abdominal fat accumulation according to vitamin D status in patients with type 2 diabetes.

**METHODS**

**Subjects**

Data from patients with type 2 diabetes who visited the diabetes clinic at Soonchunhyang University Bucheon Hospital from 2011 to 2014 were analyzed retrospectively. Patients with type 2 diabetes (n = 995) who underwent regular outpatient clinic follow-up for more than 2 years were included. The following patients were excluded: (1) patients (n = 378) in whom abdominal ultrasonography was not performed, (2) those (n = 92) who were taking calcium, vitamin D supplementation or osteoporosis therapies or had uncontrolled thyroid or parathyroid disease, (3) those (n = 120) in whom serum vitamin D levels were not measured, and (4) those (n = 103) who had other chronic liver diseases, any viral hepatitis patients and viral carriers, hemochromatosis patients, any hepatic malignancy patients and alcoholic liver disease patients or heavy alcohol drinkers (more than 140 g/wk of pure alcohol).

The remaining 302 patients with type 2 diabetes were ultimately included. We used patient medical records to carefully review their demographic and biochemical data. This study was approved by the Institutional Review Board of Soonchunhyang University Bucheon Hospital (IRB No. 2017-10-020). The informed consent was exempted from the Institutional Review Board because this study is a retrospective and analytical study.

**Laboratory biomarker measurements**

Laboratory biomarkers measured included fasting glucose, glycated hemoglobin (HbA1c), C-peptide, insulin, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and serum creatinine. Ion-exchange high-performance liquid chromatography (Bio-Rad, Hercules, CA, USA) was used to measure HbA1c. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the following formula: fasting insulin (µIU/mL) × fasting plasma glucose (mg/dL)/405.

The vitamin D status was evaluated by measuring the level of 25-hydroxyvitamin D (25(OH)D), a commonly used marker for vitamin D status. 25(OH)D concentration was measured using a radioimmunoassay (CIS Bio International, Paris, France). Patients were divided into three groups according to their 25(OH)D levels: the vitamin D deficient group (n = 116, 25(OH)D < 10 ng/mL), the vitamin D insufficient group (n = 118, 10 ng/mL ≤ 25(OH)D < 20 ng/mL) and the vitamin D sufficient group (n = 68, 25(OH)D ≥ 20 ng/mL). Cutoff levels for vitamin D status were as defined in the World Health Organization guidelines and by the Institute of Medicine.\textsuperscript{21,22}

**Abdominal fat and NAFLD assessment**

Ultrasonography was used to assess visceral fat thickness (VFT) and abdominal subcutaneous fat thickness (SFT). The distance between the posterior aspect of the rectus abdominis muscle and the anterior wall of the aorta was defined as VFT\textsuperscript{23} and the maximal thickness of the fat tissue layer from the skin-fat interface to the linea alba was defined as SFT. A single experienced investigator measured abdominal fat thickness using a high-resolution B-mode ultrasonography. The 3.5-MHz convex-array probe and a 12-MHz linear-array probe were used to measure VFT and SFT, respectively. The intraobserver technical measurement errors for VFT and SFT were between 1.4%–2.3% and 1.1%–1.7%, respectively. Skilled radiologists and gastroenterologists performed the abdominal ultrasonography. Hepatic steatosis was diagnosed based on characteristic sonographic features, i.e., diffuse hyper-echogenicity of the liver relative to the kidneys, vascular blurring and ultrasound beam attenuation.

**Statistical analysis**

SPSS version 14.0 software (SPSS Inc., Chicago, IL, USA) was used to conduct the statistical analysis. Results are summarized with mean and standard deviation for continuous variables. Skewed
distributed variables, like fasting glucose, HbA1c, AST, ALT and lipid profiles, were log-transformed and then analyzed. A chi-square test was performed to compare categorical variables. A student t-test was used to evaluate the significance of the mean differences including 25(OH)D levels in patients with and without NAFLD and in those without NAFLD. One-way analysis of variance was performed to evaluate the differences of means among groups according to the 25(OH)D levels. The correlation between serum 25(OH)D and clinical parameters was analyzed with Pearson or Spearman correlation analyses. Multivariate logistic regression was performed to determine the odds ratios (ORs) for NAFLD after adjusting for other variables. P-values less than 0.05 were considered as statistically significant.

**RESULTS**

The prevalences of vitamin D deficient and vitamin D sufficient patients among patients with type 2 diabetes were 38.4% and 22.5%, respectively. The prevalence of NAFLD in all patients with type 2 diabetes included in the study was 62.9%. The mean levels of 25(OH)D were 21.7 ± 14.1 ng/mL and 15.1 ± 9.7 ng/mL in patients with type 2 diabetes with or without NAFLD, respectively (P = 0.003).

The clinical and demographic characteristics of patients are described in Table 1. The mean ages of vitamin D deficient, vitamin D insufficient, and vitamin D sufficient groups were 59.1, 55.3, and 59.9 years. Body mass index (BMI) was not statistically different

| Variable          | Vitamin D deficient group (n = 116) | Vitamin D insufficient group (n = 118) | Vitamin D sufficient group (n = 68) | P       |
|-------------------|-------------------------------------|---------------------------------------|-----------------------------------|---------|
| Anthropometric parameter |                                      |                                       |                                   |         |
| Age (yr)          | 59.1 ± 15.8                         | 55.3 ± 16.1                           | 59.9 ± 15.6                       | 0.390   |
| Male sex (%)      | 23.5                                | 48.8                                  | 43.2                              | 0.070   |
| BMI (kg/m²)       | 24.4 ± 4.0                          | 24.8 ± 4.2                            | 25.2 ± 3.8                        | 0.378   |
| Hypertension (%)  | 47.1                                | 41.5                                  | 59.5                              | 0.378   |
| SBP (mmHg)        | 123.8 ± 15.6                        | 128.1 ± 17.1                          | 123.9 ± 16.6                      | 0.431   |
| DBP (mmHg)        | 72.5 ± 11.1                         | 78.0 ± 10.9                           | 75.2 ± 10.7                       | 0.096   |
| Duration of diabetes (yr) | 8.0 ± 10.6                        | 6.8 ± 5.6                             | 7.1 ± 6.3                         | 0.782   |
| Biochemical metabolic parameter |                                  |                                       |                                   |         |
| 25(OH)D (ng/mL)   | 7.0 ± 2.3                           | 14.6 ± 2.8                            | 30.9 ± 10.9                       | < 0.001 |
| FPG (mg/dL)       | 165.5 ± 69.9                        | 162.6 ± 66.5                          | 209.8 ± 120.5                     | 0.593   |
| HbA1c (%)         | 9.4 ± 1.9                           | 10.5 ± 2.4                            | 10.6 ± 3.4                        | 0.136   |
| Total cholesterol (mg/dL) | 173.0 ± 50.2                      | 172.2 ± 59.9                          | 168.2 ± 73.9                      | 0.937   |
| Triglyceride (mg/dL) | 166.1 ± 161.8                     | 163.4 ± 104.2                         | 178.3 ± 138.5                     | 0.907   |
| HDL cholesterol (mg/dL) | 39.8 ± 47.1                      | 35.4 ± 43.9                           | 35.5 ± 41.9                       | 0.178   |
| LDL cholesterol (mg/dL) | 88.9 ± 117.2                      | 87.4 ± 124.2                          | 78.2 ± 95.6                       | 0.133   |
| AST (IU/L)        | 28.0 ± 25.0                         | 24.9 ± 16.2                           | 22.2 ± 13.1                       | 0.227   |
| ALT (IU/L)        | 31.5 ± 33.6                         | 31.9 ± 26.3                           | 27.7 ± 24.9                       | 0.677   |
| Creatinine (mg/dL) | 1.2 ± 0.6                           | 1.4 ± 1.1                             | 1.2 ± 0.4                         | 0.300   |
| Fasting insulin (mU/mL) | 7.6 ± 6.7                         | 9.8 ± 7.3                             | 12.6 ± 12.5                       | 0.103   |
| Fasting C-peptide (ng/mL) | 2.1 ± 1.4                      | 2.9 ± 2.0                             | 3.6 ± 3.5                         | 0.037   |
| HOMA-IR           | 4.4 ± 5.4                           | 2.5 ± 2.1                             | 3.6 ± 3.1                         | 0.112   |
| Treatment modality |                                  |                                       |                                   | 0.032   |
| No treatment (%)  | 23.5                                | 25.7                                  | 22.2                              |         |
| OHA (%)           | 35.3                                | 34.3                                  | 36.1                              |         |
| Insulin (%)       | 35.3                                | 20.0                                  | 22.2                              |         |
| OHA+insulin (%)   | 5.9                                 | 17.1                                  | 19.4                              |         |

Values are presented as mean ± standard deviation. Chi-square test was used to compare sex, hypertension, and treatment modality. Vitamin D deficient group, 25(OH)D < 10 ng/mL; Vitamin D insufficient group, 10 ng/mL ≤ 25(OH)D < 20 ng/mL; Vitamin D sufficient group, 25(OH)D ≥ 20 ng/mL; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 25(OH)D, 25-hydroxyvitamin D; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment of insulin resistance; OHA, oral hypoglycemic agent.
between the three groups (24.4 ± 4.0 kg/m² in the vitamin D deficient group, 24.8 ± 4.2 kg/m² in the vitamin D insufficient group, and 25.2 ± 3.8 kg/m² in the vitamin D sufficient group; P = 0.378).

Levels of fasting plasma C-peptide were significantly increased according to the increase in 25(OH)D (2.1 ± 1.4 ng/mL in the vitamin D deficient group, 2.9 ± 2.0 ng/mL in the vitamin D insufficient group, and 3.6 ± 3.5 ng/mL in the vitamin D sufficient group, P = 0.037). However, no statistical differences in serum fasting plasma glucose, HbA1c, lipid profiles, AST, ALT and HOMA-IR were found according to 25(OH)D status.

Serum 25(OH)D levels were positively correlated with systolic blood pressure, fasting C-peptide, and fasting insulin (Table 2). VFT was significantly higher in the vitamin D deficient group compared to in the vitamin D sufficient group (54.6 mm vs. 44.6 mm, P = 0.001), but no differences in SFT were found to correlate with 25(OH)D status (Fig. 1). The prevalence of NAFLD was significantly higher in the vitamin D deficient group compared to the vitamin D sufficient and vitamin D insufficient groups (75.0% vs. 36.4% vs. 64.0%, P = 0.001) (Fig. 2). In multivariate logistic analysis, after adjustment for age, sex, BMI, HbA1c, and HOMA-IR, ORs and 95% confidence intervals for NAFLD in both the vitamin D sufficient (0.109 [0.035–0.342], P < 0.001) and vitamin D insufficient groups (0.244 [0.075–0.793], P = 0.019) were significantly lower than in the vitamin D deficient group (Table 3).

**DISCUSSION**

According to the Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV), vitamin D insufficiency is very common among Koreans. In our cohort, only 22.5% of...
patients had serum vitamin D levels above 30 ng/mL. The results of our study suggest that low vitamin D levels are associated with NAFLD and abdominal visceral fat accumulation in Korean patients with type 2 diabetes. In this study, the lower prevalence of NAFLD among patients with higher levels of vitamin D remained significant even after adjusting for possible confounding factors like age, sex, BMI, HbA1c, and HOMA-IR. Some studies have also demonstrated the association between levels of vitamin D and the risk of NAFLD. Moreover, a recent study based on data from the U.S. Third National Health and Nutrition Examination Survey reported that vitamin D levels were associated with mortality from diabetes and Alzheimer disease in NAFLD. A randomized prospective study consisting of 81 NAFLD patients showed that the addition of vitamin D along with lifestyle modification resulted in significant improvements in serum ALT and adiponectin levels. Because vitamin D is known to be involved in immune regulation, cell differentiation and proliferation, and inflammatory responses, low levels of vitamin D are thought to play a part in the pathogenesis of NAFLD by upregulating hepatic inflammation through adipocytokines.

In our study, no differences in glycemic control, HOMA-IR, BMI, or abdominal SFT were found between groups with different 25(OH)D status. However, abdominal VFT was significantly higher in the vitamin D deficient group compared to the vitamin D sufficient group. Previous data has suggested that abdominal obesity is significantly associated with vitamin D deficiency. Cheng et al. reported that lower vitamin D levels were associated with greater regional adiposity in the Framingham Heart Study. In a Malaysian study, vitamin D insufficiency was independently associated with greater abdominal obesity. These studies reported that the association between vitamin D and visceral fat was more potent than with abdominal subcutaneous fat.

In this study, serum 25(OH)D levels were not correlated with glycemic control and HOMA-IR, but did correlate significantly with fasting C-peptide and insulin levels. Results from previous studies on the association between vitamin D deficiency and glycemic control and insulin resistance in patients with type 2 diabetes have been inconsistent. The presence of vitamin D receptors on pancreatic β cells and the presence of a vitamin D response element in the insulin gene are suggested mechanisms for the effect of vitamin D on pancreatic β cells. A prospective study by Kayaniyil et al. reported that higher vitamin D levels independently predicted better β-cell function in type 2 diabetes. However, a case-control study by Fondjo et al. reported there was no association between vitamin D deficiency and insulin resistance or β cell function. These results are thought to be inconsistent due to differences in race, ethnicity, obesity and nutritional status. For our current study, since the participants were patients with type 2 diabetes, previous usage of oral hypoglycemic agents may have interfered with the HOMA-IR results.

Our current study has several limitations. First, since our study was designed to be cross-sectional, we could not determine the causal relationship between vitamin D levels and NAFLD and abdominal visceral fat accumulation. Second, due to the lack of data, we could not classify NAFLD by severity. Other possible important factors confounding the vitamin D levels, like outside activity, dietary habits and seasonal variations in vitamin D, were also not included in our study. Sex difference also is an important factor. Stadlmayr et al. reported that vitamin D levels are independently associated with type 2 diabetes in women, but not in men. Verdoia et al. also reported that lower vitamin D levels in women play a more relevant role in conditioning the severity of coronary artery disease than in men. Also, as previously known, sex is an important factor in the assessment of abdominal fat and NAFLD. However, in our current study, probably due to lack of data, we could not derive significant results from differences in sex. Nevertheless, we adjusted for sex difference in our multivariate logistic analysis of vitamin D.

Table 3. Multivariate logistic regression analysis with the presence and absence of NAFLD as the dependent variable

| Variable          | Odds ratio (95% CI) | P    |
|-------------------|---------------------|------|
| Age               | 0.968 (0.935–1.003) | 0.071|
| Sex (male)        | 0.780 (0.302–2.011) | 0.606|
| BMI               | 1.156 (1.017–1.313) | 0.026|
| HbA1c            | 1.007 (0.858–1.182) | 0.930|
| 25(OH)D (ng/mL)  |                     |      |
| < 10              | 1                   | <0.001|
| ≥ 10 & < 20       | 0.244 (0.075–0.793) | 0.019|
| ≥ 20              | 0.109 (0.035–0.342) |      |
| HOMA-IR          | 1.072 (0.935–1.230) | 0.317|

NAFLD, nonalcoholic fatty liver disease; CI, confidence interval; BMI, body mass index; HbA1c, glycated hemoglobin; 25(OH)D, 25-hydroxyvitamin D; HOMA-IR, homeostasis model assessment of insulin resistance.
and NAFLD. Due to lack of data, the above-mentioned factor including the sex difference should be investigated in a future study. Finally, since our study was based on a single clinical center, there is a possibility of selection bias on the results. Nonetheless, this single-center study also conferred a high degree of consistency with respect to laboratory data and the evaluation of NAFLD.

Despite these limitations, our study has strength in that the patients were divided into three groups based upon their vitamin D status, and the important metabolic variables in each group were compared and evaluated with each other group. Moreover, this study had a high degree of consistency with respect to laboratory data and the evaluation of NAFLD. The association of vitamin D with the development of many chronic diseases has been the focus of much research recently. The important role of vitamin D on the development of metabolic disease including NAFLD has been established, but many more studies are needed because the data are still incoherent. In this study, the vitamin D deficient group had a thicker VFT and higher NAFLD prevalence than either the vitamin D sufficient or vitamin D insufficient groups. Larger prospective studies will be required to elucidate the associations between vitamin D levels and NAFLD and abdominal fat in patients with type 2 diabetes.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

This work was supported by the Soonchunhyang University Research Fund.

REFERENCES

1. Poole KE, Loveridge N, Barker PJ, Halsall DJ, Rose C, Reeve J, et al. Reduced vitamin D in acute stroke. Stroke 2006;37:243-5.
2. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008;168:1174-80.
3. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006;98:451-9.
4. Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 2010;340:b5500.
5. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009;169:384-90.
6. Mattila C, Knek P, Männistö S, Rissanen H, Laaksonen MA, Montonen J, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 2007;30:2569-70.
7. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92:2017-29.
8. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004;79:820-5.
9. Maki KC, Fulgoni VL 3rd, Keast DR, Rains TM, Park KM, Rubin MR. Vitamin D intake and status are associated with lower prevalence of metabolic syndrome in U.S. adults: National Health and Nutrition Examination Surveys 2003-2006. Metab Syndr Relat Disord 2012;10:363-72.
10. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005;90:1578-82.
11. Shin SR, Han AL, Park SH. Vitamin D status and its relation with abdominal adiposity and cardiovascular risk factors of Korean adults in certain areas. Korean J Obes 2015;24:30-5.
12. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
13. Targher G, Bertolini L, Poli F, Rodela S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovas-
cular events among type 2 diabetic patients. Diabetes 2005;54:3541-6.
14. Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016;65:1096-108.
15. Ganji V, Zhang X, Tangpricha V. Serum 25-hydroxyvitamin D concentrations and prevalence estimates of hypovitaminosis D in the U.S. population based on assay-adjusted data. J Nutr 2012;142:498-507.
16. Bhatt SP, Misra A, Sharma M, Guleria R, Pandey RM, Luthra K, et al. Vitamin D insufficiency is associated with abdominal obesity in urban Asian Indians without diabetes in North India. Diabetes Technol Ther 2014;16:392-7.
17. Hannemann A, Thuesen BH, Friedrich N, Völzke H, Steveling A, Ittermann T, et al. Adiposity measures and vitamin D concentrations in Northeast Germany and Denmark. Nutr Metab (Lond) 2015;12:24.
18. Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010;33:1379-81.
19. Herrmann A, Sullivan DR, Veillard AS, McCorquodale T, Straub IR, Scott R, et al. Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care 2015;38:521-8.
20. Bajaj S, Singh RP, Dwivedi NC, Singh K, Gupta A, Mathur M. Vitamin D levels and microvascular complications in type 2 diabetes. Indian J Endocrinol Metab 2014;18:537-41.
21. Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT. Vitamin D status: United States, 2001-2006. NCHS Data Brief 2011;(59):1-8.
22. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
23. Kawamoto R, Ohtsuka N, Ninomiya D, Nakamura S. Association of obesity and visceral fat distribution with intima-media thickness of carotid arteries in middle-aged and older persons. Intern Med 2008;47:143-9.
24. Choi HS, Oh HJ, Choi H, Choi WH, Kim JG, Kim KM, et al. Vitamin D insufficiency in Korea: a greater threat to younger generation. The Korea National Health and Nutrition Examination Survey (KNHANES) 2008. J Clin Endocrinol Metab 2011;96:643-51.
25. Eliades M, Syprou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38:246-54.
26. Wang X, Li W, Zhang Y, Yang Y, Qin G. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. Int J Clin Exp Med 2015;8:17221-34.
27. Kim HS, Rotundo L, Kothari N, Kim SH, Pyrsopoulos N. Vitamin D is associated with severity and mortality of non-alcoholic fatty liver disease: a US population-based study. J Clin Transl Hepatol 2017;5:185-92.
28. Kwok RM, Torres DM, Harrison SA. Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology 2013;58:1166-74.
29. Cheng S, Massaro JM, Fox CS, Larson MG, Keyes MJ, McCabe EL, et al. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes 2010;59:242-8.
30. Moy FM, Bulgiba A. High prevalence of vitamin D insufficiency and its association with obesity and metabolic syndrome among Malay adults in Kuala Lumpur, Malaysia. BMC Public Health 2011;11:735.
31. Talaei A, Mohamadi M, Adgi Z. The effect of vitamin D on insulin resistance in patients with type 2 diabetes. Diabetol Metab Syndr 2013;5:8.
32. Fondjo LA, Owiredu WK, Sakyi SA, Laing EF, Adotey-Kwofie MA, Antoh EO, et al. Vitamin D status and its association with insulin resistance among type 2 diabetic: a case-control study in Ghana. PLoS One 2017;12:e0175388.
33. Afzal S, Bojesen SE, Nordestgaard BG. Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis. Clin Chem 2013;59:381-91.
34. Kayaniyil S, Retnakaran R, Harris SB, Vieth R, Knight JA, Gerstein HC, et al. Prospective associations of vitamin D with β-cell function and glycaemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes
2011;60:2947-53.

35. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006;92:39-48.

36. Maestro B, Dávila N, Carranza MC, Calle C. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003;84:223-30.

37. Stadlmayr A, Aigner E, Huber-Schönauer U, Niederseer D, Zwerina J, Husar-Memmer E, et al. Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetol 2015;52:39-46.

38. Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, et al. Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. Nutr Metab Cardiovasc Dis 2015;25:464-70.